<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39311952</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1250</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Zeitschrift fur Rheumatologie</Title><ISOAbbreviation>Z Rheumatol</ISOAbbreviation></Journal><ArticleTitle>[Corona vaccination under immunosuppression].</ArticleTitle><Pagination><StartPage>544</StartPage><EndPage>548</EndPage><MedlinePgn>544-548</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00393-024-01555-2</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to play a major role as a severe and potentially fatal airway infection, especially in vulnerable patient groups. In view of the thin data situation on the influence of treatment and response to vaccination, at the beginning of the corona pandemic it was a major challenge to predict the tolerability and effectiveness in patients with inflammatory rheumatic diseases under immunomodulation or immunosuppression. In the meantime, numerous studies have addressed the questions of response and tolerability, at least for the COVID-19 vaccination. Even in the first months of the vaccination campaign, a small study on a single center cohort could show that apart from patients with B‑cell depletion, all included patients showed a seroconversion after the first two vaccinations. This resulted in neither an increased occurrence of exacerbations of the underlying disease nor new autoimmune phenomena. Various studies have since then confirmed these data.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hasseli-Fräbel</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sektion für Rheumatologie und Klinische Immunologie, Universitätsklinikum Münster, Münster, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kneitz</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatologische Schwerpunktpraxis Schwerin, Schwerin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voll</LastName><ForeName>R E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Klinik für Rheumatologie und Klinische Immunologie, Universitätsklinikum Freiburg und Medizinische Fakultät, Freiburg, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyer</LastName><ForeName>B F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Rheumatologie und klin. Immunologie, Christian-Albrechts-Universität Kiel, Kiel, Deutschland. bfhoyer@rheuma.uni-kiel.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Institut für Luft- und Raumfahrtmedizin, DLR e. V., Köln, Deutschland. bfhoyer@rheuma.uni-kiel.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Coronaimpfung unter Immunsuppression.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Rheumatol</MedlineTA><NlmUniqueID>0414162</NlmUniqueID><ISSNLinking>0340-1855</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>SARS-CoV‑2 („severe acute respiratory syndrome coronavirus type 2“) spielt auch weiterhin eine große Rolle als schwere und potenziell tödliche Atemwegsinfektion insbesondere bei vulnerablen Patient:innengruppen. Angesichts der dünnen Datenlagen zum Einfluss von Therapien auf Impfantworten war es zu Beginn der Corona-Pandemie eine große Herausforderung, die Verträglichkeit und Wirksamkeit bei Patient:innen mit entzündlich rheumatischen Erkrankungen unter Immunmodulation/Immunsuppression vorherzusagen. Inzwischen haben zahlreiche Studien die Fragen nach Ansprechen und Verträglichkeit zumindest für die COVID-19(Coronavirus-Erkrankung 2019)-Impfung adressiert. Bereits in den ersten Monaten der Impfkampagne konnte eine kleine Studie an einer monozentrischen Kohorte zeigen, dass bis auf Patient:innen unter B‑Zell-Depletion alle eingeschlossenen Patient:innen in der Lage waren, nach den ersten 2 Impfungen eine Serokonversion zu zeigen. Dabei kam es weder zu einem vermehrten Auftreten von Schüben der Grunderkrankungen noch zu neuen Autoimmunphänomenen. Diverse Studien haben diese Daten seitdem bestätigt.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B‑cell depletion</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">Inflammatory rheumatic diseases</Keyword><Keyword MajorTopicYN="N">SARS-CoV‑2</Keyword><Keyword MajorTopicYN="N">Seroconversion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39311952</ArticleId><ArticleId IdType="doi">10.1007/s00393-024-01555-2</ArticleId><ArticleId IdType="pii">10.1007/s00393-024-01555-2</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>Arumahandi De Silva AN, Frommert LM, Albach FN et al (2022) Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann Rheum Dis 81:881–888</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221876</ArticleId><ArticleId IdType="pubmed">35288376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijlsma JW, Force EC‑T (2022) EULAR 2021 updated viewpoints on SARS-CoV‑2 vaccination in patients with RMDs: a guidance to answer patients’ questions. Ann Rheum Dis 81:786–788</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221965</ArticleId><ArticleId IdType="pubmed">35121591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli M, Mrak D, Tobudic S et al (2022) Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV‑2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis 81:687–694</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221558</ArticleId><ArticleId IdType="pubmed">35027397</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmegna I, Valerio V, Amiable N et al (2023) COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series. RMD Open 9:</Citation></Reference><Reference><Citation>Deepak P, Kim W, Paley MA et al (2021) Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV‑2 : A Prospective Cohort Study. Ann Intern Med 174:1572–1585</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1757</ArticleId><ArticleId IdType="pubmed">34461029</ArticleId></ArticleIdList></Reference><Reference><Citation>Durez P, Combe B (2023) Should we stop methotrexate or not for vaccination? RMD Open 9:</Citation></Reference><Reference><Citation>Eviatar T, Furer V, Polachek A et al (2024) Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls. J Rheumatol 51:415–422</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.2023-0357</ArticleId><ArticleId IdType="pubmed">37914221</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L, Gerstel PF, Poncet A et al (2015) Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases—a longitudinal study. Arthritis Res Ther 17:151</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0663-9</ArticleId><ArticleId IdType="pubmed">26048579</ArticleId><ArticleId IdType="pmc">4481118</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S, Connolly C, Chiang P‑YT et al (2022) Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV‑2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease. Arthritis Rheumatol 74:</Citation></Reference><Reference><Citation>Friedman MA, Curtis JR, Winthrop KL (2021) Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 80:1255–1265</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221244</ArticleId><ArticleId IdType="pubmed">34493491</ArticleId></ArticleIdList></Reference><Reference><Citation>Frolke SC, Bouwmans P, Messchendorp AL et al (2022) Predictors of Nonseroconversion to SARS-CoV‑2 Vaccination in Kidney Transplant Recipients. Transplant Direct 8:e1397</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TXD.0000000000001397</ArticleId><ArticleId IdType="pubmed">36245996</ArticleId><ArticleId IdType="pmc">9553374</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Cirera S, Calvet J, Berenguer-Llergo A et al (2022) Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV‑2 mRNA vaccines in Systemic Lupus Erythematosus patients. Sci Rep 12:14772</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-18996-x</ArticleId><ArticleId IdType="pubmed">36042275</ArticleId><ArticleId IdType="pmc">9427088</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisen UM, Berner DK, Tran F et al (2021) Immunogenicity and safety of anti-SARS-CoV‑2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis</Citation></Reference><Reference><Citation>Geisen UM, Rose R, Neumann F et al (2022) The long term vaccine-induced anti-SARS-CoV‑2 immune response is impaired in quantity and quality under TNFalpha blockade. J Med Virol 94:5780–5789</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28063</ArticleId><ArticleId IdType="pubmed">35945627</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisen UM, Sumbul M, Tran F et al (2021) Humoral protection to SARS-CoV 2 declines faster in patients on TNF alpha blocking therapies. RMD Open 7:</Citation></Reference><Reference><Citation>Hasseli R, Mueller-Ladner U, Hoyer BF et al (2021) Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7:</Citation></Reference><Reference><Citation>Kobie JJ, Zheng B, Bryk P et al (2011) Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 13:R209</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3542</ArticleId><ArticleId IdType="pubmed">22177419</ArticleId><ArticleId IdType="pmc">3334662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn T, Speer C, Morath C et al (2023) Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose. Transplantation 107:1139–1150</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004516</ArticleId><ArticleId IdType="pubmed">36617671</ArticleId><ArticleId IdType="pmc">10125015</ArticleId></ArticleIdList></Reference><Reference><Citation>Landewe RBM, Kroon FPB, Alunno A et al (2022) EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 81:1628–1639</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-222006</ArticleId><ArticleId IdType="pubmed">35197264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D, Simader E, Sieghart D et al (2022) Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Ann Rheum Dis 81:1750–1756</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222579</ArticleId><ArticleId IdType="pubmed">35977809</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Lee YJ, Shin K et al (2018) Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 77:898–904</Citation><ArticleIdList><ArticleId IdType="pubmed">29572291</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Joyce D, Haag K et al (2023) Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response. Arthritis Care Res 75:1878–1885</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.25094</ArticleId></ArticleIdList></Reference><Reference><Citation>Plasencia-Rodriguez C, Martinez-Feito A, Hernandez M et al (2023) Immune response after SARS-CoV‑2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment. Allergy Asthma Clin Immunol 19:71</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13223-023-00832-0</ArticleId><ArticleId IdType="pubmed">37598192</ArticleId><ArticleId IdType="pmc">10439605</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu M, Cabrera-Martinez B, Winslow GM (2019) TNF-alpha Contributes to Lymphoid Tissue Disorganization and Germinal Center B Cell Suppression during Intracellular Bacterial Infection. J Immunol 203:2415–2424</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900484</ArticleId><ArticleId IdType="pubmed">31570507</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer A, Kovacs MS, Eder A et al (2023) TNF inhibitors significantly attenuate the humoral immune response to COVID-19 vaccination in patients with rheumatoid arthritis. Rheumatol Adv Pract 7:rkad65</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkad065</ArticleId><ArticleId IdType="pubmed">37560623</ArticleId><ArticleId IdType="pmc">10406699</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiff AE, Wang X, Patel NJ et al (2023) Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study. medRxiv</Citation></Reference><Reference><Citation>Specker C, Ad-Hoc-Kommission C‑DD, Schulze-Koops H et al (2021) Vaccination against SARS-CoV‑2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients. Z Rheumatol 80:43–44</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-020-00955-4</ArticleId><ArticleId IdType="pubmed">33438061</ArticleId><ArticleId IdType="pmc">7802998</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanski AL, Rincon-Arevalo H, Schrezenmeier E et al (2022) B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV‑2 Vaccination Among Patients Treated With Rituximab. Arthritis Rheumatol 74:934–947</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42060</ArticleId><ArticleId IdType="pubmed">34962360</ArticleId><ArticleId IdType="pmc">9011692</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens KI, Frangou E, Shin JIL et al (2022) Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrol Dial Transplant 37:1400–1410</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac052</ArticleId><ArticleId IdType="pubmed">35244174</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas K, Grigoropoulos I, Alexopoulou P et al (2024) Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV‑2. Rheumatology 63:534–541</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead236</ArticleId><ArticleId IdType="pubmed">37228039</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniutto P, Cussigh A, Cmet S et al (2023) Mycophenolate Interruption Restores Anti-SARS-CoV‑2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients. Vaccines 11:</Citation></Reference><Reference><Citation>Yu B, Tamargo C, Brennan DC, Kant S (2023) Measures to Increase Immunogenicity of SARS-CoV‑2 Vaccines in Solid Organ Transplant Recipients: A Narrative Review. Vaccines 11(12):1755. https://doi.org/10.3390/vaccines11121755</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121755</ArticleId><ArticleId IdType="pubmed">38140160</ArticleId><ArticleId IdType="pmc">10748337</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/21_23.pdf?__blob=publicationFile</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>